It inhibited ferroptotic CRC cell death by blocking dipeptidyl-peptidase-4 (DPP4) activity, while the loss of p53 increased the anticancer activity of erastin in tumour-bearing mice, very different from the positive regulation of ferroptosis by p53 in other cancers (Fig. 3)61. The gene discussed is DPP4; the disease is neoplasm.